A5056083434- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Renal and related cancers
- Renal cell carcinoma treatment
- Cancer Research and Treatments
- Cancer therapeutics and mechanisms
- Gastric Cancer Management and Outcomes
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Hepatocellular Carcinoma Treatment and Prognosis
- Biochemical and Molecular Research
- Neutropenia and Cancer Infections
- Colorectal and Anal Carcinomas
- Microtubule and mitosis dynamics
- Chemotherapy-related skin toxicity
- Cancer-related Molecular Pathways
- Genetic factors in colorectal cancer
- Salivary Gland Tumors Diagnosis and Treatment
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Head and Neck Cancer Studies
- Colorectal Cancer Surgical Treatments
- Cancer, Hypoxia, and Metabolism
- Immunotherapy and Immune Responses
- Pancreatic and Hepatic Oncology Research
Wilmington University
2024
Dynavax Technologies (United States)
2018-2023
Amgen (United States)
2013-2018
Institut de Cancérologie de l'Ouest
2011-2018
Inserm
2006-2017
Centre Hospitalier Universitaire de Tours
2004-2017
Pfizer (United States)
2017
Université Bretagne Loire
2016
Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers
2009-2015
Gefluc Languedoc Roussillon
1995-2014
A phase III, multicenter, randomized study compared conventional dosing of fluorouracil (FU) plus folinic acid with pharmacokinetically guided FU dose adjustment in terms response, tolerability, and survival.Two hundred eight patients measurable metastatic colorectal cancer were randomly assigned to one two arms: arm (104 patients; 96 assessable), which the was calculated based on body-surface area; B 90 individually determined using adjustments. The initial regimen 1,500 mg/m(2) 200...
Tumor-associated macrophages (TAM) are M2d-polarized cells (IL-10(high), IL-12(low), ILT3(high), CD86(low)) that accumulate in tumor microenvironment. TAM inhibit antitumor T lymphocyte generation and function, contribute to tolerance trophic for tumors. In this study, we investigated whether some immunological factors may reverse immunosuppressive properties. Among 32 cytokines, have identified IFNgamma on its ability switch into immunostimulatory cells. Upon exposure, purified from ovarian...
Oxaliplatin is active in colorectal cancer. Sensory neurotoxicity its dose-limiting toxicity. It may come from an effect on neuronal voltage-gated Na channels, via the liberation one metabolite, oxalate. We decided to use Ca and Mg as oxalate chelators.A retrospective cohort of 161 patients treated with oxaliplatin + 5-fluorouracil leucovorin for advanced cancer, three regimens (85 mg/m(2)/2w, 100/2w, 130/3w) was identified. Ninety-six received infusions gluconate sulfate (1 g) before after...
Oxaliplatin, a new widely used anticancer drug, displays frequent, sometimes severe, acute sensory neurotoxicity accompanied by neuromuscular signs that look like the symptoms observed in tetany and myotonia. The whole cell patch-clamp technique was employed to investigate oxaliplatin effects on electrophysiological properties of short-term cultured dorsal unpaired median (DUM) neurons isolated from CNS cockroach Periplaneta americana. Within clinical concentration range, (40-500 microM),...
Abstract Purpose: We wanted to assess polymorphisms in the uridine diphosphoglucuronosyl transferase 1A1 (UGT 1A1) gene: TATA box polymorphism and UGT G71R Y486D mutations coding sequence, main characterizing Gilbert’s syndrome, as predictors of severe toxic event occurrence after irinotecan (CPT-11) administration. Therefore, we set up a rapid, sensitive, reliable technique routine practice detect before CPT-11 treatment, at-risk patients. Experimental Design: Seventy-five patients with...
Isolated hepatic metastases of colorectal cancer constitute a frequent and serious therapeutic problem that has led to the evaluation arterial infusion (HAI) different drugs. Oxaliplatin combined with fluorouracil (FU) leucovorin is effective in treatment cancer. In this context, phase II study was conducted evaluate concomitant administration oxaliplatin by HAI intravenous (IV) FU plus according LV5FU2 protocol (leucovorin 200 mg/m(2), 400 mg/m(2) IV bolus, 600 22-hour continuous on days 1...
Abstract Purpose: Although single nucleotide polymorphisms (SNP) of the dihydropyrimidine dehydrogenase gene (DPYD) have been reported, which affect enzyme activity and severity 5-fluorouracil (5-FU) toxicity, no pretherapeutic detection has thus far developed. We investigated 22 DPYD SNPs, their respective incidence, link with grade 3 to 4 toxic side effects, management in practice: 9 were looked for 487 patients, whereas 13 others 171 patients. Patients Methods: SNPs detected before...
BACKGROUND A phase II prospective trial was carried out to study the concept of 5-fluorouracil (5-FU) dose-intensity in patients with advanced colorectal cancer. Forty were treated 5-FU plus leucovorin (LV), individually increasing doses 5-FU. pharmacokinetic follow up performed and a relationship sought between its metabolism response treatment, 5-FU's toxicity patient survival. METHODS administered weekly by 8 hour continuous infusion. The initial dose 1000 mg/m2 increased every 3 weeks...
PURPOSE: Patients with genetic fluorouracil (5-FU) catabolic deficiencies are at high risk for severe toxicity. To predict 5-FU and toxic side effects, we conducted a prospective study of patients treated advanced colorectal cancer by high-dose 5-FU. PATIENTS AND METHODS: Eighty-one were weekly infusions folinic acid. The initial dose 1,300 mg/m 2 was individually adjusted according to dose-adjustment chart. Plasma concentrations uracil (U) its dihydrogenated metabolite, dihydrouracil (UH ),...
Expression profiles represent new molecular tools that are useful to characterize the successive steps of tumor progression and prediction recurrence or chemotherapy response. In this study, we have used quantitative proteomic analysis compare different stages colorectal cancer. A combination laser microdissection, OFFGEL separation, iTRAQ labeling, MALDI-TOF/TOF MS was explore proteome 28 cancer tissues. Two software packages were for identification quantification differentially expressed...
PURPOSE A relationship between fluorouracil (5-FU) dose and response has been previously shown in advanced colorectal cancer. In a previous study with 5-FU stepwise escalation weekly regimen, pharmacokinetic monitoring, we defined therapeutic range for plasma levels: 2,000 to 3,000 microg/L (area under the concentration-time curve at 0 8 hours [AUC0-8], 16 24 mg x h/L). The current investigated intensification individual adjustment multicentric phase II prospective trial. PATIENTS AND...
Abstract Purpose: Oxaliplatin displays a frequent dose-limiting neurotoxicity due to its interference with neuron voltage-gated sodium channels through one of metabolites, oxalate, calcium chelator. Different clinical approaches failed in prevention, except calcium-magnesium infusions. We characterized oxalate outcome following oxaliplatin administration and cations amino acids. then looked for genetic predictive factors oxaliplatin-induced neurotoxicity. Experimental Design: first tested...
Abstract Purpose: An ancillary phase II study was conducted to interindividual variability in cetuximab pharmacokinetics and its influence on progression-free survival (PFS) metastatic colorectal cancer patients cotreated with irinotecan 5-fluorouracil. Experimental Design: Ninety-six received as an infusion loading dose of 400 mg/m2 followed by weekly infusions 250 mg/m2. Doses 5-fluorouracil were adjusted individually. Cetuximab concentrations measured ELISA. Compartmental pharmacokinetic...